This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
Rett Syndrome Update: Evolving Management Strategies (CME/CE)
MedEdicus Podcasts
12 minutes
2 years ago
Rett Syndrome Update: Evolving Management Strategies (CME/CE)
Access the disclosures, evaluation, and your CME credit via: https://courses.mededicus.com/content/rtt-syndrome-update-evolving-management-strategies-cmece-podcast Dr Jeffrey Neul is an internationally recognized expert in Rett Syndrome and other genetic neurodevelopmental disorders. In this podcast, he talks to us about current guideline-directed management, clinical data for the first ever treatment for Rett syndrome, and another emerging disorder-specific therapy that is on the horiz...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
